Semaglutide
Semaglutide
Semaglutide is a synthetic peptide studied in in-vitro and preclinical research as a GLP-1 receptor agonist. Research reagent only — not for human consumption or medical use.

Key facts
- Class
- GLP-1 agonist
- Target
- GLP-1 receptor
- Form
- Lyophilised (powder)
- Status
- Research Use Only
Study library
All results on PubMedSemaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M, et al. · Lancet (London, England) · 2021
Wegovy (semaglutide): a new weight loss drug for chronic weight management.
Singh G, et al. · Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2022
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.
Bikou A, et al. · Expert opinion on pharmacotherapy · 2024
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Pratley RE, et al. · The lancet. Diabetes & endocrinology · 2018
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Sorli C, et al. · The lancet. Diabetes & endocrinology · 2017
Semaglutide: First Global Approval.
Dhillon S · Drugs · 2018
As Ozempic's Popularity Soars, Here's What to Know About Semaglutide and Weight Loss.
Suran M · JAMA · 2023
Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice.
Bensignor MO, et al. · Current opinion in pediatrics · 2024
Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.
Feier CVI, et al. · International journal of molecular sciences · 2024
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.
Friedrichsen M, et al. · Diabetes, obesity & metabolism · 2021
Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist.
Hall S, et al. · Clinical pharmacokinetics · 2018
Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.
Wang W, et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
Results retrieved live from PubMed (NCBI). Research literature only — no medical advice.
Research peptides — Research Use Only
- Not for human consumption
- Not for the diagnosis, treatment or prevention of any disease
